These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 12956767

  • 21. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 22. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 23. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
    Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group.
    J Thromb Haemost; 2005 Jul 01; 3(7):1503-10. PubMed ID: 15978108
    [Abstract] [Full Text] [Related]

  • 24. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
    Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M.
    Blood Coagul Fibrinolysis; 2003 Sep 01; 14(6):551-6. PubMed ID: 12960608
    [Abstract] [Full Text] [Related]

  • 25. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 01; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 26. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 27. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 28. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T.
    Diabetes Care; 2005 Sep 06; 28(9):2211-6. PubMed ID: 16123492
    [Abstract] [Full Text] [Related]

  • 29. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 06; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 30. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 06; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 31. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May 06; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 32. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 06; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 33. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
    Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi MC.
    Thromb Haemost; 2005 Aug 06; 94(2):373-9. PubMed ID: 16113828
    [Abstract] [Full Text] [Related]

  • 34. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep 06; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 35. Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
    Dubis J, Zuk N, Grendziak R, Zapotoczny N, Pfanhauser M, Witkiewicz W.
    Blood Coagul Fibrinolysis; 2014 Apr 06; 25(3):226-31. PubMed ID: 24378973
    [Abstract] [Full Text] [Related]

  • 36. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
    Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC.
    Thromb Res; 2009 Nov 06; 124(5):614-8. PubMed ID: 19699511
    [Abstract] [Full Text] [Related]

  • 37. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
    Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH.
    J Thromb Haemost; 2004 Jan 06; 2(1):54-7. PubMed ID: 14717966
    [Abstract] [Full Text] [Related]

  • 38. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
    Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB.
    Clin Chim Acta; 2014 Jun 10; 433():76-83. PubMed ID: 24631134
    [Abstract] [Full Text] [Related]

  • 39. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
    Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Haemost; 2003 Dec 10; 90(6):1187-91. PubMed ID: 14652655
    [Abstract] [Full Text] [Related]

  • 40. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct 10; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.